1 Pharma Stock to Buy on Strong Vaccine Growth Potential
NASDAQ · 3h ago
Arcturus, CSL win approval for world’s first self-amplifying mRNA vaccine in Japan
Healthcare arcturus, csl win approval for world’s first self-amplifying mrna vaccine in japan. Japan's ministry of health approves arct-154 covid-19 vaccine. Arcturus therapeutics and partner csl say it's the world's first regulatory clearance of a self-amplifying mrna.
Seeking Alpha · 3h ago
Moderna starts building mRNA plant in China
Healthcare moderna starts building mrna plant in china. All products from the plant will be for domestic distribution. Moderna has started building its first production plant for messenger-rna-based medicines in shanghai. The vaccine specialist has more than 40 mrna products in its pipeline.
Seeking Alpha · 8h ago
Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up
NASDAQ · 10h ago
SPY ETF Update, 11/28/2023
TipRanks · 12h ago
QQQ ETF Update, 11/28/2023
TipRanks · 16h ago
Weekly Report: what happened at MRNA last week (1120-1124)?
Weekly Report · 1d ago
Black Friday On Wall Street: 10 S&P 500 Stocks Trading At 40%+ Discount From Analysts' Expectations
Several s&p 500 stocks are trading at significant discounts compared to their average year-ahead price targets set by analysts. Discounts can arise due to market volatility, economic downturns or industry-specific issues. 10 stocks are currently trading at discounts of over 40% compared to analysts' average price targets.
Benzinga · 4d ago
Pneumonia outbreak in China is no reason for alarm: WHO
Healthcare pneumonia outbreak in china is no reason for alarm: who. World health organization advised against imposing travel restrictions after outbreak of respiratory illnesses in china. Outbreak sparked fears of a novel pathogen similar to the covid-19 pandemic four years ago. Who says there were no detections of novel pathogens or unusual clinical presentations.
Seeking Alpha · 4d ago
$100 Invested In Moderna 5 Years Ago Would Be Worth This Much Today
Moderna has outperformed the market over the past 5 years by 22.22%. Mrna has an average annual return of 33.37%. Moderna has a market capitalization of $29.93 billion. If an investor bought $100 of mrna stock 5 years ago, it would be worth $422.04 today.
Benzinga · 4d ago
SPY ETF Update, 11/24/2023
Spy is up 0.86% in the past 5 days and has risen nearly 21% year-to-date. The spdr s&p 500 etf trust is a moderate buy, according to tipranks. The street's average price target of $506.46 implies an upside of 11.30%. Spy's five holdings have the highest upside potential.
TipRanks · 4d ago
QQQ ETF Update, 11/24/2023
Invesco qqq trust etf is up 0.63% in the past 5 days and 48.1% year-to-date. The invesco etf is a strong buy, according to tipranks' analyst consensus. The street’s average price target of $428.51 implies an upside of 9.9%.
TipRanks · 4d ago
SPY ETF Update, 11/23/2023  
TipRanks · 5d ago
Analyzing ARKG's Trading Activity In Q3
Ark genomic revolution etf focuses on genomic innovation in sectors such as healthcare, information technology, and energy. The fund's buying and selling activity gives us clues about the fund's trading activity in the third quarter of 2013. Arkg is a passively managed exchange-traded fund.
Seeking Alpha · 5d ago
Don’t Let the Q3 Earnings Miss Keep You From These 3 Stocks!
NASDAQ · 5d ago
5 Reasons to Track the Nasdaq-100
NASDAQ · 6d ago
BioNTech Vs. Moderna: Navigating The mRNA Landscape
Moderna and biontech are pioneering companies in messenger rna (mrna) technology. Both companies are known for their fast development of highly effective covid-19 vaccines. Mrna technology has the potential to transform the treatment landscape for cancer and infectious diseases. After the pandemic boom both companies stock prices have declined significantly. Picking up shares of moderna may be worth considering due to their innovative approaches and growth prospects.
Seeking Alpha · 6d ago
3 Biotech Stocks That Could Be Millionaire Makers
Three high-growth biotech companies could be millionaire makers. Crispr therapeutics, moderna and axsome therapeutic are among them. Moderna is on track to launch as many as 15 new products in the next five years. Axsome has the world's first approval for a gene-editing treatment.
The Motley Fool · 6d ago
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
Moderna, Inc. is a biotechnology company. The Company is focused on developing messenger ribonucleic acid (mRNA) therapeutics and vaccines. It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range spectrum of diseases. The Company's products include Spikevax, the Moderna COVID-19 vaccine (mRNA-1273), a bivalent vaccine targeting the BA.1 Omicron variant, combined with Spikevax (mRNA-1273.214), and bivalent vaccine targeting the BA.4/BA.5 Omicron variants combined with Spikevax (mRNA-1273.222). It has a development pipeline of 45 development candidates across its 48 development programs, of which 38 are in clinical studies.